What is the recommended treatment and dosage for Keppra (levetiracetam) in patients with epilepsy?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: August 11, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Levetiracetam (Keppra) Treatment for Epilepsy

The recommended treatment for epilepsy with levetiracetam (Keppra) is to start with 1000 mg/day (500 mg twice daily) for adults, with titration up to 3000 mg/day in 1000 mg increments every 2 weeks as needed, while children should start at 20 mg/kg/day divided into two doses with titration up to 60 mg/kg/day. 1

Indications

Levetiracetam is FDA-approved for:

  • Adjunctive treatment of partial onset seizures in adults and children ≥4 years
  • Adjunctive therapy for myoclonic seizures in adults and adolescents ≥12 years with juvenile myoclonic epilepsy
  • Adjunctive therapy for primary generalized tonic-clonic seizures in adults and children ≥6 years with idiopathic generalized epilepsy 1

Dosing Guidelines by Age and Seizure Type

Adults (≥16 years)

  • Partial Onset Seizures:

    • Initial dose: 1000 mg/day (500 mg twice daily)
    • Titration: Increase by 1000 mg/day every 2 weeks
    • Maximum recommended dose: 3000 mg/day (1500 mg twice daily) 1
  • Myoclonic Seizures (≥12 years):

    • Initial dose: 1000 mg/day (500 mg twice daily)
    • Titration: Increase by 1000 mg/day every 2 weeks
    • Target dose: 3000 mg/day 1
  • Primary Generalized Tonic-Clonic Seizures:

    • Initial dose: 1000 mg/day (500 mg twice daily)
    • Titration: Increase by 1000 mg/day every 2 weeks
    • Target dose: 3000 mg/day 1

Pediatric Patients

  • Ages 4 to <16 years (Partial Onset Seizures):

    • Initial dose: 20 mg/kg/day in 2 divided doses
    • Titration: Increase by 20 mg/kg every 2 weeks
    • Target dose: 60 mg/kg/day (30 mg/kg twice daily) 1
  • Ages 6 to <16 years (Primary Generalized Tonic-Clonic Seizures):

    • Initial dose: 20 mg/kg/day in 2 divided doses
    • Titration: Increase by 20 mg/kg every 2 weeks
    • Target dose: 60 mg/kg/day (30 mg/kg twice daily) 1

Administration Guidelines

  • Levetiracetam can be taken with or without food 1
  • For children ≤20 kg, use oral solution
  • For children >20 kg, either tablets or oral solution can be used 1
  • For patients with renal impairment, dose adjustment is required based on creatinine clearance 2:
    • Creatinine clearance 50-80 ml/min: 500-1000 mg every 12 hours

Special Considerations

Seizure Prophylaxis

  • For patients with CNS disease or history of seizures receiving CAR T-cell therapy, levetiracetam 10 mg/kg (maximum 500 mg per dose) every 12 hours for 30 days is recommended for seizure prophylaxis 3

Status Epilepticus

  • Loading dose: 30 mg/kg IV (maximum 2500 mg) administered at 5 mg/kg per minute 2
  • For children with status epilepticus: 30-50 mg/kg IV over 10-15 minutes 2

Efficacy and Safety Profile

  • Levetiracetam has demonstrated efficacy with 67-73% control rate in refractory status epilepticus 2
  • In clinical trials, levetiracetam showed dose-dependent efficacy with significantly decreased seizure frequency at doses of 1000,2000, and 3000 mg/day compared to placebo 4
  • At 1000 mg/day, 5.5% of patients became seizure-free, and at 2000 mg/day, 6.3% became seizure-free 4

Common Adverse Effects

  • Somnolence (10.5-15.2%)
  • Asthenia
  • Dizziness
  • Irritability 2

Risk Factors for Adverse Effects

  • Patients with intellectual disability or psychiatric history have higher risk (12-15%) of behavioral adverse effects 2
  • For these high-risk patients, slower titration and closer monitoring are recommended 2

Clinical Pearls

  • Approximately 89% of patients do not report significant adverse effects after loading doses 2
  • Levetiracetam has minimal drug interactions, making it particularly useful for patients on multiple medications 2
  • Most patients respond at lower doses - in clinical studies, 80.1% of patients achieving 6-month remission did so at the lowest dose level 5
  • Doses above 3000 mg/day have been used in open-label studies but without evidence of additional benefit 1
  • For children, doses above 20 mg/kg/day should be introduced with caution 2

Levetiracetam's favorable safety profile, minimal drug interactions, and proven efficacy make it a valuable option for epilepsy treatment across multiple seizure types and age groups.

References

Guideline

Seizure Management

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.